Recruiting studies: Resectable Skin Squamous Cell Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Radiotherapy in Combination With Atezolizumab in Locally Advanced Borderline Resectable or Unresectable Cutaneous SCC
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT05085496 Neoadjuvant Pembrolizumab in Cutaneous Squamous Cell Carcinoma
Phase 2 · 3 location(s) · Queensland Health · NCT05025813 Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
Phase 2 · 15 location(s) · IO Biotech · NCT05280314 Neoadjuvant Nivolumab and Relatlimab in Cutaneous Squamous Cell Carcinoma
Phase 2 · 1 location(s) · Melanoma Institute Australia · NCT06288191 Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer
Phase 2 · 1 location(s) · University of Michigan Rogel Cancer Center · NCT07094685

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.